Drug Profile
Tizaterkib - Antengene Corporation
Alternative Names: ATG-017; AZD-0364Latest Information Update: 28 Sep 2023
Price :
$50
*
At a glance
- Originator AstraZeneca
- Developer Antengene Corporation; AstraZeneca
- Class Antineoplastics; Fluorobenzenes; Imidazoles; Pyrazines; Pyrazoles; Pyrimidines; Small molecules
- Mechanism of Action Mitogen activated protein kinase 3 inhibitors; Mitogen-activated protein kinase 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Acute myeloid leukaemia; Haematological malignancies; Multiple myeloma; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Solid tumours
Most Recent Events
- 28 Sep 2023 No recent reports of development identified for phase-I development in Haematological-malignancies(Combination therapy, Late-stage disease) in Australia (PO)
- 28 Sep 2023 No recent reports of development identified for phase-I development in Haematological-malignancies(Combination therapy, Late-stage disease) in USA (PO)
- 28 Sep 2023 No recent reports of development identified for phase-I development in Haematological-malignancies(Late-stage disease, Monotherapy) in Australia (PO)